Metsera (NASDAQ:MTSR) Hits New 1-Year High - What's Next?

Key Points

• Metsera Inc. (NASDAQ:MTSR) reached a new 52-week high of $53.65, significantly up from its previous close of $33.32, with a trading volume of over 2.77 million shares.
• Wall Street analysts have a generally positive outlook on MTSR, with several upgrades including a target price increase from $56.00 to $62.00 by Guggenheim and an "overweight" rating from Wells Fargo with a target of $65.00.
• The stock has surged 62.7% over its fifty-day moving average, reflecting strong investor interest and institutional buying during the first quarter.

Metsera Inc. (NASDAQ:MTSR - Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $53.65 and last traded at $53.65, with a volume of 2778391 shares traded. The stock had previously closed at $33.32.

Analyst Upgrades and Downgrades

Several brokerages have commented on MTSR. Wells Fargo & Company assumed coverage on Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target on the stock. Bank of America upped their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Leerink Partnrs raised Metsera to a "strong-buy" rating in a research report on Tuesday, September 9th. Finally, Leerink Partners started coverage on Metsera in a research report on Tuesday, September 9th. They issued an "outperform" rating and a $77.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $63.50.

Metsera Price Performance

The business has a 50 day moving average of $35.71 and a 200 day moving average of $29.35.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MTSR. Alphabet Inc. bought a new position in Metsera in the 1st quarter valued at $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Metsera during the first quarter worth approximately $78,748,000. Wellington Management Group LLP bought a new position in Metsera in the 1st quarter valued at $65,382,000. Alpha Wave Global LP acquired a new stake in Metsera in the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Metsera in the 1st quarter valued at about $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.